<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(AMENDMENT NO. ___)*
ISTA PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
--------------------------------------------------------------------------------
(Title of Class of Securities)
45031X10
--------------------------------------------------------------------------------
(CUSIP Number)
August 24, 2000
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
----------------------
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
Page 1 of 7 pages
<PAGE> 2
------------------- -----------------
CUSIP NO. 45031X10 13G PAGE 2 OF 7 PAGES
------------------- -----------------
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
ALLERGAN PHARMACEUTICALS (IRELAND) LTD., INC.
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
PANAMA
-------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF 1,309,780
SHARES --------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 0
EACH --------------------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON WITH 1,309,780
--------------------------------------------------------
8 SHARED DISPOSITIVE POWER
0
-------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,309,780
-------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES* [ ]
-------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
8.93%
-------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
CO
-------------------------------------------------------------------------------
<PAGE> 3
------------------- -----------------
CUSIP NO. 45031X10 13G PAGE 3 OF 7 PAGES
------------------- -----------------
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
ALLERGAN HOLDINGS, INC.
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
-------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF 1,309,780
SHARES --------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 0
EACH --------------------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON WITH 1,309,780
--------------------------------------------------------
8 SHARED DISPOSITIVE POWER
0
-------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,309,780
-------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES* [ ]
-------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
8.93%
-------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
CO
-------------------------------------------------------------------------------
<PAGE> 4
------------------- -----------------
CUSIP NO. 45031X10 13G PAGE 4 OF 7 PAGES
------------------- -----------------
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
ALLERGAN, INC.
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
-------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF 1,309,780
SHARES --------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 0
EACH --------------------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON WITH 1,309,780
--------------------------------------------------------
8 SHARED DISPOSITIVE POWER
0
-------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,309,780
-------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES* [ ]
-------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
8.93%
-------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
CO
-------------------------------------------------------------------------------
<PAGE> 5
ITEM 1.
(a) Name of Issuer: ISTA Pharmaceuticals, Inc. ("ISTA")
(b) Address of ISTA's Principal Executive
Offices: 15279 Alton Parkway, Building 100
Irvine, CA 92618
ITEM 2.
(a) Name of Person Filing: Allergan Pharmaceuticals (Ireland)
Ltd., Inc.*
Allergan Holdings, Inc.
Allergan, Inc.
* The subject ISTA shares are owned beneficially and of
record by Allergan Pharmaceuticals (Ireland), Inc., which
is a wholly-owned subsidiary of Allergan Holdings, Inc.
Allergan Holdings, Inc., in turn, is a wholly-owned
subsidiary of Allergan, Inc. Given this corporate
structure, all three Allergan entities are deemed to
beneficially own the subject ISTA shares, and therefore
all three entities are named in this Schedule 13G.
(b) Address of Principal Business Office or, if none, Residence:
2525 Dupont Drive
Irvine, CA 92612
(c) Place of Organization: Allergan Pharmaceuticals (Ireland) Ltd.,
Inc. - Panama
Allergan Holdings, Inc. - Delaware
Allergan, Inc. - Delaware
(d) Title of Class of Securities: Common Stock
(e) CUSIP Number: 45031X10
ITEM 3. NOT APPLICABLE.
ITEM 4 OWNERSHIP.
(a) Amount Beneficially Owned: Each corporation is deemed to have
beneficially owned 1,309,780 shares of Common Stock of ISTA as of
August 24, 2000.
(b) Percent of Class: 8.93%
(c) Number of shares as to which such person has:
<TABLE>
<CAPTION>
<S> <C>
(i) sole power to vote or to direct the vote: 1,309,780
(ii) shares power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the disposition of: 1,309,780
(iv) shared power to dispose or to direct the disposition of: 0
</TABLE>
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following: [ ]
Page 5 of 7 pages
<PAGE> 6
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
See response under Item 2(a) above.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable.
ITEM 10. CERTIFICATION
By signing below, I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not
acquired and are not held in connection with or as a participant in
any transaction having that purpose or effect.*
* This Schedule 13G is filed in connection with the acquisition by
Allergan Pharmaceuticals (Ireland) Ltd., Inc. (API), in a
transaction that closed on or about August 24, 2000, of an
aggregate of 285,714 shares of ISTA Common Stock. This
acquisition took place in connection with ISTA's initial public
offering of Common Stock (the ISTA IPO). Prior to the ISTA IPO,
API had owned an aggregate of 1,776,199 shares of ISTA's Series
D Preferred Stock, which automatically converted into 1,024,066
shares of ISTA Common Stock upon the effectiveness of the ISTA
IPO. As a result of API's acquisition of 285,714 newly issued
shares of Common Stock in the ISTA IPO, API's percentage
ownership of ISTA (net of the dilutive effect of the ISTA IPO as
a whole), increased from 8.8% to 8.93% as of August 24, 2000.
Page 6 of 7 pages
<PAGE> 7
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: September 1, 2000
ALLERGAN PHARMACEUTICALS (IRELAND) LTD., INC.
By: /s/ AIMEE S. WEISNER
-------------------------------------------
Aimee S. Weisner, Assistant Secretary
ALLERGAN HOLDINGS, INC.
By: /s/ AIMEE S. WEISNER
-------------------------------------------
Aimee S. Weisner, Assistant Secretary
ALLERGAN, INC.
By: /s/ AIMEE S. WEISNER
-------------------------------------------
Aimee S. Weisner, Assistant Secretary
Page 7 of 7 pages
